A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
The company takes a PD-L1 x VEGF asset into phase 3.
A new phase 3, Manifest-3, will start in April to support US filing.
New first-in-human study initiations feature yet more in vivo Car assets.
Intismeran autogene’s Interpath-001 trial reads out this year.
Armed with $75m the company takes a risky asset into the clinic.
